Biomarkers for gastric cancer: Prognostic, predictive or targets of therapy?

Virchows Archiv

Volumn 464, Issue 3, 2014, Pages 367-378

  Durães, Cecília ^a   Almeida, Gabriela M ^a   Seruca, Raquel ^a,b   Oliveira, Carla ^a,b   Carneiro, Fátima ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Biomarkers; Gastric cancer; Patient stratification; Predictive; Prognostic; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GAMMA UROGASTRONE; HUMAN EPIDERMAL GROWTH FACTOR 2; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; NIMOTUZUMAB; ONARTUZUMAB; OXALIPLATIN; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RAMUCIRUMAB; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN A;

ANGIOGENESIS; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CELL VIABILITY; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; ENZYME ACTIVE SITE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; INFANCY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATION RATE; OUTCOME ASSESSMENT; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SYSTEMIC THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897048556     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1533-y     Document Type: Review

References (89)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893-2917. doi:10.1002/ijc.25516
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Ca-a Cancer Journal for Clinicians 61(2):69-90. doi:10.3322/Caac.20107
3. Houghton J, Wang TC (2005) Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 128(6):1567-1578 (Pubitemid 40692553)
4. Yamashita K, Sakuramoto S, Katada N, Futawatari N, Moriya H, Hirai K, Kikuchi S, Watanabe M (2009) Diffuse type advanced gastric cancer showing dismal prognosis is characterized by deeper invasion and emerging peritoneal cancer cell: the latest comparative study to intestinal advanced gastric cancer. Hepatogastroenterology 56(89):276-281
5. Oliveira C, Seruca R, Carneiro F (2009) Hereditary gastric cancer. Best Pract Res Clin Gastroenterol 23(2):147-157. doi:10.1016/j.bpg.2009.02.003
6. Oliveira C, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, Corso G, Schouten J, Fitzgerald R, Vogelsang H, Keller G, Dwerryhouse S, Grimmer D, Chin SF, Yang HK, Jackson CE, Seruca R, Roviello F, Stupka E, Caldas C, Huntsman D (2009) Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 18(9):1545-1555. doi:10.1093/hmg/ddp046
7. Mihaljevic AL, Friess H, Schuhmacher C (2013) Clinical trials in gastric cancer and the future. J Surg Oncol 107(3):289-297. doi:10.1002/Jso.23120
8. Takeuchi H, Kitagawa Y (2013) New sentinel node mapping technologies for early gastric cancer. Ann Surg Oncol 20(2):522-532. doi:10.1245/s10434-012-2602- 1
9. Kitagawa Y, Takeuchi H, Takagi Y, Natsugoe S, Terashima M, Murakami N, Fujimura T, Tsujimoto H, Hayashi H, Yoshimizu N, Takagane A, Mohri Y, Nabeshima K, Uenosono Y, Kinami S, Sakamoto J, Morita S, Aikou T, Miwa K, Kitajima M (2013) Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan. J Clin Oncol. doi:10.1200/JCO.2013.50.3789
10. Cervantes A, Roda D, Tarazona N, Rosello S, Perez-Fidalgo JA (2013) Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 39(1):60-67. doi:10.1016/j.ctrv.2012.09.007
11. GASTRIC Group, Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Tsuburaya A, Van Cutsem E, Buyse M(2013) Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer 49(7):1565-1577. doi:10.1016/j.ejca.2012.12.016
12. Italiano A (2011) Prognostic or predictive? It's time to get back to definitions! J Clin Oncol 29(35):4718. doi:10.1200/JCO.2011.38.3729, author reply 4718-4719
13. Pietrantonio F, Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M (2013) A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res 33(4):1257-1266
14. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th edn. New York, Springer
15. Japanese Research Society for Gastric Cancer (1993) The general rules for the gastric cancer study in surgery and pathology, 12 edn. Japanese Research Society for Gastric Cancer, Kanahara Shuppan, Tokyo
16. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22(12):2395-2403. doi:10.1200/JCO.2004.08.154 (Pubitemid 41121931)
17. Chau I, Ashley S, Cunningham D (2009) Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data fromthe REAL 2 study. J Clin Oncol 27(19):e3-e4. doi:10.1200/JCO.2009.22.0863
18. Sehdev A, Catenacci DV (2013) Gastroesophageal cancer: focus on epidemiology, classification, and staging. Discov Med 16(87):103-111
19. Lee J, Ou SH (2013) Towards the goal of personalized medicine in gastric cancer - time to move beyond HER2 inhibition. Part I: targeting receptor tyrosine kinase gene amplification. Discov Med 15(85):333-341
20. Ou SH (2012) Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 83(3):407-421. doi:10.1016/j.critrevonc.2011.11.010
21. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19(9):1523-1529. doi:10.1093/annonc/mdn169
22. Hofmann M, StossO, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J, Henkel T (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7): 797-805. doi:10.1111/j.1365-2559.2008.03028.x (Pubitemid 351724903)
23. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16(2):273-278. doi:10.1093/annonc/mdi064 (Pubitemid 40309309)
24. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X
25. Bar-Sela G, Hershkovitz D, Haim N, Kaidar-Person O, Shulman K, Ben-Izhak O (2013) The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. Oncol Lett 5(2): 559-563. doi:10.3892/ol.2012.1031
26. Barros-Silva JD, Leitao D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rego S, Brandao C, Carneiro F, Lopes C, Schmitt F, Teixeira MR (2009) Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 100(3): 487-493. doi:10.1038/sj.bjc.6604885
27. Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, Ochiai A (2013) Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. doi:10.1007/s10120-013-0239-9
28. Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ, Press MF (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.Ann Oncol 24(7):1754-1761. doi:10.1093/annonc/mdt106
29. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W (2010) HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 32(1-2):57-65. doi:10.3233/CLO-2009-0497
30. Okines AF, Thompson LC, Cunningham D, Wotherspoon A, Reis-Filho JS, Langley RE, Waddell TS, Noor D, Eltahir Z, Wong R, Stenning S (2013) Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol 24(5):1253-1261. doi:10.1093/annonc/mds622
31. Hudis CA (2007) Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357(1):39-51. doi:10.1056/NEJMra043186
32. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ, team Hs (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer: a randomised controlled trial. Lancet 369(9555):29-36. doi:10.1016/S0140-6736(07)60028-2
33. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl JMed 344(11):783-792. doi:10.1056/NEJM200103153441101 (Pubitemid 32222155)
34. Kiyose S, Nagura K, Tao H, Igarashi H, Yamada H, Goto M, Maeda M, Kurabe N, Suzuki M, Tsuboi M, Kahyo T, Shinmura K, Hattori N, Sugimura H (2012) Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. Pathol Int 62(7):477-484. doi:10.1111/j.1440-1827.2012. 02832.x
35. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61(5):673-684. doi:10.1136/gutjnl-2011- 301839
36. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH (2008) EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52(6):738-746. doi:10.1111/j.1365-2559.2008.03021.x (Pubitemid 351600058)
37. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29(36):4789-4795. doi:10.1200/JCO.2011.36.7706
38. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G (2008) Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15(1):69-79. doi:10.1245/s10434-007-9596-0
39. Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS (2011) A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol 22(6):1367-1373. doi:10.1093/annonc/mdq604
40. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Gotte H, Melezinkova H, Moehler M, Arbeitsgemeinschaft Internistische O, Investigators E (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14(6):490-499. doi:10.1016/S1470-2045(13)70102-5
41. Okines AF, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, Saffery C, Chua YJ, Chau I (2010) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 28(25): 3945-3950. doi:10.1200/JCO.2010.29.2847
42. Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Hofler H, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, Lordick F (2011) Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/ 5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 11:509. doi:10.1186/1471-2407-11-509
43. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY (2009) Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100(2): 298-304. doi:10.1038/sj.bjc.6604861
44. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S, German Arbeitsgemeinschaft Internistische O (2011) Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 22(6):1358-1366. doi:10.1093/annonc/mdq591
45. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Storkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13(1): 33-42. doi:10.1016/S1470-2045(11)70318-7
46. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y (2000) Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 153(1-2):7-12 (Pubitemid 30209837)
47. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl JMed 350(23):2335-2342. doi:10.1056/NEJMoa032691 (Pubitemid 38702844)
48. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-2550. doi:10.1056/ NEJMoa061884 (Pubitemid 44917502)
49. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30):3968-3976. doi:10.1200/JCO.2011.36.2236
50. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA (2012) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30(17):2119-2127. doi:10.1200/JCO.2011.39.9824
51. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J, for the RTI (2013) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. doi:10.1016/S0140-6736(13)61719-5
52. Kilgour E, Su X, Zhan P, Gavine P, Morgan S, Womack C, Jung E-J, Bang Y-J, Im S-A, Kim W, Grabsch H (2012) Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts. J Clin Oncol 30(15-suppl):4124
53. Jung EJ, Jung EJ, Min SY, Kim MA, Kim WH (2012) Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol 43(10):1559- 1566. doi:10.1016/j.humpath.2011.12. 002
54. Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q (2013) FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 19(9):2572-2583. doi:10.1158/1078-0432.CCR-12-3898
55. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25(6):1517-1524. doi:10.3892/or.2011.1219
56. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29(36):4803-4810. doi:10.1200/JCO.2011.35.4928
57. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, Bang YJ, Kim WH (2012) MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107(2):325-333. doi:10.1038/bjc.2012.237
58. Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA (2011) MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 20(5):1021-1027. doi:10.1158/1055-9965.EPI-10-1080
59. Taguchi F, Kodera Y, Katanasaka Y, Yanagihara K, Tamura T, Koizumi F (2011) Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs 29(6):1198-1205. doi:10.1007/s10637- 010-9464-9
60. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK, Stoeltzing O (2007) Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimentalmodel. Int J Cancer 120(8):1803-1810. doi:10.1002/ijc.22442 (Pubitemid 46399369)
61. Xu DZ, Geng QR, Tian Y, Cai MY, Fang XJ, Zhan YQ, Zhou ZW, Li W, Chen YB, Sun XW, Guan YX, Li YF, Lin TY (2010) Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer 10:536. doi:10.1186/1471-2407-10-536
62. Yu G,Wang J, Chen Y,Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K (2009) Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 15(5):1821-1829. doi:10.1158/1078-0432.CCR-08-2138
63. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E (2013) Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 Study. J Clin Oncol. doi:10.1200/JCO.2012.48.3552
64. Yoon DH, Ryu MH, Park YS, Lee HJ, Lee C, Ryoo BY, Lee JL, Chang HM, Kim TW, Kang YK (2012) Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106(6):1039-1044. doi:10.1038/bjc.2012.47
65. Samuels Y,Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554. doi:10.1126/science.1096502 (Pubitemid 38541907)
66. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S Jr, Duval A, Carneiro F, Machado JC, Hamelin R, Seruca R (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41(11):1649-1654. doi:10.1016/j.ejca.2005.04.022 (Pubitemid 40981849)
67. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, Kang SY, Park JO, Kang WK, MacConaill L, Kim KM (2012) High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 7(6):e38892. doi:10.1371/journal.pone.0038892
68. Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, JiM, Xu L, He N, Shi B, Hou P (2012) Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 12:50. doi:10.1186/1471-2407-12-50
69. Barbi S, Cataldo I, De Manzoni G, Bersani S, Lamba S, Mattuzzi S, Bardelli A, Scarpa A (2010) The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 29:32. doi:10.1186/1756-9966-29- 32
70. Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, Moehler M (2012) Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 69(6):1601-1615. doi:10.1007/s00280-012-1869-z
71. Pinto M, Oliveira C, Machado JC, Cirnes L, Tavares J, Carneiro F, Hamelin R, Hofstra R, Seruca R, Sobrinho-Simoes M (2000) MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathological profile. Lab Invest 80(12):1915-1923 (Pubitemid 32012759)
72. Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, Milanezi F, Pascale V, Vindigni C, Pinheiro H, Leite M, Marrelli D, Sousa S, Carneiro F, Oliveira C, Roviello F, Seruca R (2011) Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer 47(3):443-451. doi:10.1016/j.ejca.2010. 09.008
73. Oliveira C, Seruca R, Seixas M, Sobrinho-Simoes M (1998) The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. Am J Pathol 153(4):1211-1219
74. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R, Schwartz S Jr (2003) BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22(57):9192-9196. doi:10.1038/sj.onc.1207061 75.
75. van Grieken NC, Aoyma T, Chambers PA, Bottomley D, Ward LC, Inam I, Buffart TE, Das K, Lim T, Pang B, Zhang SL, Tan IB, Carvalho B, Heideman DA, Miyagi Y, Kameda Y, Arai T, Meijer GA, Tsuburaya A, Tan P, Yoshikawa T, Grabsch HI (2013) KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer fromthe East and theWest: results from a large international multicentre study. Br J Cancer 108(7):1495-1501. doi:10.1038/bjc.2013.109
76. Brennetot C, Duval A, Hamelin R, Pinto M, Oliveira C, Seruca R, Schwartz S Jr (2003) Frequent Ki-ras mutations in gastric tumors of the MSI phenotype. Gastroenterology 125(4):1282
77. Warneke VS, Behrens HM, Haag J, Balschun K, Boger C, Becker T, Ebert MP, Lordick F, Rocken C (2013) Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol 22(3):127-137. doi:10.1097/PDM.0b013e318284188e
78. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626-1634. doi:10.1200/JCO.2007.14.7116
79. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) Kras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17):1757-1765. doi:10.1056/NEJMoa0804385
80. Wittinghofer A, Scheffzek K, Ahmadian MR (1997) The interaction of Ras with GTPase-activating proteins. FEBS Lett 410(1):63-67 (Pubitemid 27283385)
81. Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, Diosdado B, Grabsch H, Santos MA, Meijer G, Seruca R, Carvalho B, Oliveira C (2012) Lack of microRNA-101 causes Ecadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol 228(1):31-44. doi:10.1002/path.4032
82. Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B, Seruca R, Roviello F, Oliveira C (2013) Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 31(7):868-875. doi:10.1200/JCO.2012.44.4612
83. Ferreira P, Oliveira MJ, Beraldi E, Mateus AR, Nakajima T, Gleave M, Yokota J, Carneiro F, Huntsman D, Seruca R, Suriano G (2005) Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Exp Cell Res 310(1):99-104. doi:10.1016/j.yexcr.2005.07.010 (Pubitemid 41393691)
84. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA Jr (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66(2):944-950. doi:10.1158/0008-5472.CAN-05-1988 (Pubitemid 43165962)
85. Xin HW, Yang JH, Nguyen DM (2013) Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma. Anticancer Res 33(6):2401-2408
86. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ, Asia Pacific Working Group on Gastric C (2008) Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 9(3):279-287. doi:10.1016/S1470-2045(08) 70072-X (Pubitemid 351722947)
87. Thekkek N, Muldoon T, Polydorides AD, Maru DM, Harpaz N, Harris MT, Hofstettor W, Hiotis SP, Kim SA, Ky AJ, Anandasabapathy S, Richards-Kortum R (2012) Vital-dye enhanced fluorescence imaging of GI mucosa: metaplasia, neoplasia, inflammation. Gastrointest Endosc 75(4):877-887. doi:10.1016/j.gie. 2011.10.004
88. Catenacci DV, Kozloff M, Kindler HL, Polite B (2011) Personalized colon cancer care in 2010. SeminOncol 38(2):284-308. doi:10.1053/j.seminoncol.2011.01. 001
89. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R (2002) Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123(6):1804-1811. doi:10.1053/gast.2002.37070 (Pubitemid 35408304)